##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample SampleUID1_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample SampleUID1_01).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=strand_tumor=Strand information. Format: [mutation_plus]|[mutation_minus]|[mutation_unkown],[wildtype_plus]|[wildtype_minus]|[wildtype_unkown],[amplicons_plus]|[amplicons_minus].
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, NM number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=Kaviar=Allele frequency in Kaviar database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, ExAC pLI score).
##FILTER=fv.not_cod_spli=Not a coding or splicing variant (filter_vcf).
##FILTER=fv.som_all_freq_nor=Allele frequency normal too high (filter_vcf).
##FILTER=fv.som_all_freq_tum=Allele frequency tumor is 0.05 (filter_vcf).
##FILTER=fv.som_depth_nor=Sequencing depth normal is < 8 (filter_vcf).
##FILTER=fv.som_depth_tum=Sequencing depth tumor is < 8 (filter_vcf).
##FILTER=fv.som_lt_3_reads=Less than 3 supporting tumor reads (filter_vcf).
##FILTER=fv.som_tum_loh=Loss of heterozygosity within tumor tissue (filter_vcf).
#chr	start	end	ref	obs	tumor_af	tumor_dp	filter	snp_q	strand_tumor	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	Kaviar	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	som_ihdb_c	som_ihdb_p	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info
chr2	48030838	48030838	A	T	0.4333	120		1267.0	30|22|0,26|42|0,1|1	MSH6	splice_region_variant&intron_variant	MSH6:NM_000179.2:splice_region_variant&intron_variant:LOW:exon5/9:c.3438+14A>T:,MSH6:NM_001281492.1:splice_region_variant&intron_variant:LOW:exon3/7:c.3048+14A>T:,MSH6:NM_001281493.1:splice_region_variant&intron_variant:LOW:exon4/8:c.2532+14A>T:,MSH6:NM_001281494.1:splice_region_variant&intron_variant:LOW:exon5/9:c.2532+14A>T:						rs2020911	0.400958	0.40426359154231	0.3966072		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350|Endometrial cancer,familial,608089|Mismatch repair cancer syndrome,276300];	RCV000035324.9 [benign]; RCV000074853.3 [benign]; RCV000410944.1 [benign]; 								4	GT,Leuk,TEST_SomaticAndTreatment,	198	643			n/a	n/a	MSH6 (inh=AD pLI=n/a)
chr2	48033891	48033891	T	-	0.2667	15		18.0	0|8|0,0|9|0,1|1	MSH6	splice_region_variant&intron_variant	MSH6:NM_000179.2:splice_region_variant&intron_variant:LOW:exon9/9:c.4002-10delT:,MSH6:NM_001281492.1:splice_region_variant&intron_variant:LOW:exon7/7:c.3612-10delT:,MSH6:NM_001281493.1:splice_region_variant&intron_variant:LOW:exon8/8:c.3096-10delT:,MSH6:NM_001281494.1:splice_region_variant&intron_variant:LOW:exon9/9:c.3096-10delT:						rs267608137;rs775865491	0.0000	0.42447659574468	0.2520063		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350|Endometrial cancer,familial,608089|Mismatch repair cancer syndrome,276300];	RCV000074976.2 [likely benign]; 								0		142	221			n/a	n/a	MSH6 (inh=AD pLI=n/a)
chr2	209101906	209101906	A	-	0.9375	112		2542.0	65|46|0,0|1|0,1|1	IDH1	splice_region_variant&intron_variant	IDH1:NM_001282386.1:splice_region_variant&intron_variant:LOW:exon9/9:c.1155-13delT:,IDH1:NM_001282387.1:splice_region_variant&intron_variant:LOW:exon9/9:c.1155-13delT:,IDH1:NM_005896.3:splice_region_variant&intron_variant:LOW:exon9/9:c.1155-13delT:		Citrate cycle (TCA cycle);Glutathione metabolism;Reductive carboxylate cycle (CO2 fixation)				rs57383668;rs796498057	0.982628	0.98975345559482	0.8877135		147700 [IDH1 (confirmed) Glioma,susceptibility to,somatic,137800];									0		654	9			n/a	n/a	IDH1 (inh=n/a pLI=0.00)
chr3	178922274	178922274	C	A	0.4000	30		200.0	4|8|0,10|8|0,1|1	PIK3CA	splice_region_variant&intron_variant	PIK3CA:NM_006218.3:splice_region_variant&intron_variant:LOW:exon5/20:c.1060-17C>A:		Inositol phosphate metabolism;ErbB signaling pathway;Phosphatidylinositol signaling system;mTOR signaling pathway;Apoptosis;VEGF signaling pathway;Focal adhesion;Toll-like receptor signaling pathway;Jak-STAT signaling pathway;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Leukocyte transendothelial migration;Regulation of actin cytoskeleton;Insulin signaling pathway;Type II diabetes mellitus;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1- AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS	AKT Signaling Pathway;Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK);Corticosteroids and cardioprotection;CTCF: First Multivalent Nuclear Factor;CXCR4 Signaling Pathway;EGF Signaling Pathway;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Fc Epsilon Receptor I Signaling in Mast Cells;Growth Hormone Signaling Pathway;Human Cytomegalovirus and Map Kinase Pathways;IGF-1 Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL-7 Signal Transduction;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Influence of Ras and Rho proteins on G1 to S Transition;Inhibition of Cellular Proliferation by Gleevec;Insulin Signaling Pathway;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);mTOR Signaling Pathway;Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation;Nerve growth factor pathway (NGF);NFAT and Hypertrophy of the heart (Transcription in the broken heart);PDGF Signaling Pathway;Phospholipase C Signaling Pathway;Phospholipids as signalling intermediaries;PTEN dependent cell cycle arrest and apoptosis;Rac 1 cell motility signaling pathway;Ras Signaling Pathway;Ras-Independent pathway in NK cell-mediated cytotoxicity;Regulation of BAD phosphorylation;Regulation of eIF4e and p70 S6 Kinase;Role of ERBB2 in Signal Transduction and Oncology;Role of Erk5 in Neuronal Survival;Role of nicotinic acetylcholine receptors in the regulation of apoptosis;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration;Signaling of Hepatocyte Growth Factor Receptor;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;T Cell Receptor Signaling Pathway;The Co-Stimulatory Signal During T-cell Activation;The IGF-1 Receptor and Longevity;Thrombin signaling and protease-activated receptors;TPO Signaling Pathway;Transcription factor CREB and its extracellular signals;Trefoil Factors Initiate  Mucosal Healing;Trka Receptor Signaling Pathway;Tumor Suppressor Arf Inhibits Ribosomal Biogenesis;VEGF, Hypoxia, and Angiogenesis		rs2699896	0.584665	0.56140132463523	0.5448284		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000|Breast cancer,somatic,114480|Colorectal cancer,somatic,114500|Gastric cancer,somatic,613659|Hepatocellular carcinoma,somatic,114550|Nonsmall cell lung cancer,somatic,211980|Keratosis,seborrheic,somatic,182000|Nevus,epidermal,somatic,162900|CLOVE syndrome,somatic,612918|Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501|Cowden syndrome 5,615108];	RCV000253634.1 [benign]; 								5	GT,MIPs_Etablierung,TEST_SomaticAndTreatment,cfDNA_HNSCC,	498	680			n/a	n/a	PIK3CA (inh=AR+AD pLI=1.00)
chr4	153268227	153268227	C	A	0.4146	41		99.0	17|0|0,24|0|0,1|1	FBXW7	splice_region_variant&intron_variant	FBXW7:NM_033632.3:splice_region_variant&intron_variant:LOW:exon3/11:c.585-4G>T:,FBXW7:NM_018315.4:splice_region_variant&intron_variant:LOW:exon2/10:c.345-4G>T:,FBXW7:NM_001013415.1:splice_region_variant&intron_variant:LOW:exon2/10:c.231-4G>T:		Neurodegenerative Diseases;Ubiquitin mediated proteolysis	Substrate recognition component of a SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins. Involved in the degradation of cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1	Cyclin E Destruction Pathway		rs72720002	0.0000	0.011739782858152	0.0068873											1	cfDNA,	2	293			n/a	n/a	FBXW7 (inh=n/a pLI=1.00)
chr5	112162854	112162854	T	C	0.9932	292		9427.0	186|104|0,0|0|0,2|2	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon12/16:c.1458T>C:p.Tyr486Tyr,APC:NM_001127511.2:synonymous_variant:LOW:exon10/14:c.1404T>C:p.Tyr468Tyr,APC:NM_001127510.2:synonymous_variant:LOW:exon13/17:c.1458T>C:p.Tyr486Tyr						rs2229992	0.509984	0.57798180286993	0.5752842	COSM1432175	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035064.9 [benign]; RCV000074147.1 [other]; RCV000131423.2 [benign]; RCV000275522.1 [benign]; 								3	Leuk,SomaticAndTreatment,	964	1384	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112164561	112164561	G	A	1.0000	134		4269.0	108|26|0,0|0|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon14/16:c.1635G>A:p.Ala545Ala,APC:NM_001127511.2:synonymous_variant:LOW:exon12/14:c.1581G>A:p.Ala527Ala,APC:NM_001127510.2:synonymous_variant:LOW:exon15/17:c.1635G>A:p.Ala545Ala						rs351771	0.666134	0.64811054430192	0.6433918	COSM3760868	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035066.9 [benign]; RCV000074153.1 [other]; RCV000162371.1 [benign]; RCV000375983.1 [benign]; RCV000411329.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1098	1324	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112175617	112175617	T	A	0.4375	80		697.0	4|31|0,2|43|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.4326T>A:p.Pro1442Pro,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.4272T>A:p.Pro1424Pro,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.4326T>A:p.Pro1442Pro						rs67622085	0.00559105	0.0081045428312309	0.0080963	COSM19049	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000119144.3 [benign]; RCV000131961.2 [benign]; RCV000254138.1 [benign]; RCV000361337.1 [likely benign]; 								0		0	48			n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112175770	112175770	G	A	1.0000	294		8894.0	41|253|0,0|0|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.4479G>A:p.Thr1493Thr,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.4425G>A:p.Thr1475Thr,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.4479G>A:p.Thr1493Thr						rs41115	0.665535	0.6485700596428	0.6435269	COSM3760869	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035071.9 [benign]; RCV000074234.1 [other]; RCV000162372.1 [benign]; RCV000383485.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1097	1330	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112176325	112176325	G	A	1.0000	117		3366.0	69|48|0,0|0|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.5034G>A:p.Gly1678Gly,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.4980G>A:p.Gly1660Gly,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.5034G>A:p.Gly1678Gly						rs42427	0.666733	0.65139551052841	0.6443950	COSM3760870	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035074.9 [benign]; RCV000074235.1 [other]; RCV000162373.1 [benign]; RCV000390083.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1107	1314	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112176559	112176559	T	G	0.9966	291		8663.0	76|214|0,1|0|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.5268T>G:p.Ser1756Ser,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.5214T>G:p.Ser1738Ser,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.5268T>G:p.Ser1756Ser						rs866006	0.666933	0.65076579187019	0.6434754		611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000166360.1 [likely benign]; RCV000035076.9 [benign]; RCV000074236.1 [other]; RCV000162374.1 [benign]; RCV000359973.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1099	1316	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112176756	112176756	T	A	1.0000	19		557.0	18|1|0,0|0|0,1|1	APC	missense_variant	APC:NM_000038.5:missense_variant:MODERATE:exon16/16:c.5465T>A:p.Val1822Asp,APC:NM_001127511.2:missense_variant:MODERATE:exon14/14:c.5411T>A:p.Val1804Asp,APC:NM_001127510.2:missense_variant:MODERATE:exon17/17:c.5465T>A:p.Val1822Asp						rs459552	0.865415	0.79810490805662	0.7913816	COSM3760871	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000020089.2 [benign]; RCV000034393.1 [benign]; RCV000035078.10 [benign]; RCV000074239.1 [other]; RCV000132160.2 [benign]; RCV000358689.1 [benign]; RCV000216852.1 [uncertain significance]; 	CM990164 [CLASS=DP MUT=REF PHEN="Adenomatous polyposis coli association with" GENE=APC]; 	3.653000	T	T,T,T	B,B	D,D,D	13.24	0		1696	1012	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112177171	112177171	G	A	1.0000	146		4470.0	14|132|0,0|0|0,1|1	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.5880G>A:p.Pro1960Pro,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.5826G>A:p.Pro1942Pro,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.5880G>A:p.Pro1960Pro						rs465899	0.666534	0.64880922868428	0.6437519	COSM3760872	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035080.9 [benign]; RCV000074242.1 [other]; RCV000162375.1 [benign]; RCV000270059.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1095	1325	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr7	6026775	6026775	T	C	1.0000	11		234.0	14|9|0,0|0|0,1|1	PMS2	missense_variant,non_coding_transcript_exon_variant	PMS2:NM_001322014.1:missense_variant:MODERATE:exon11/15:c.1621A>G:p.Lys541Glu,PMS2:NM_001322005.1:missense_variant:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_001322009.1:missense_variant:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_000535.6:missense_variant:MODERATE:exon11/15:c.1621A>G:p.Lys541Glu,PMS2:NM_001322003.1:missense_variant:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_001322004.1:missense_variant:MODERATE:exon10/14:c.1216A>G:p.Lys406Glu,PMS2:NM_001322006.1:missense_variant:MODERATE:exon10/14:c.1465A>G:p.Lys489Glu,PMS2:NM_001322007.1:missense_variant:MODERATE:exon10/14:c.1303A>G:p.Lys435Glu,PMS2:NM_001322008.1:missense_variant:MODERATE:exon9/13:c.1303A>G:p.Lys435Glu,PMS2:NM_001322010.1:missense_variant:MODERATE:exon9/13:c.1060A>G:p.Lys354Glu,PMS2:NM_001322011.1:missense_variant:MODERATE:exon11/15:c.688A>G:p.Lys230Glu,PMS2:NM_001322012.1:missense_variant:MODERATE:exon11/15:c.688A>G:p.Lys230Glu,PMS2:NM_001322013.1:missense_variant:MODERATE:exon10/14:c.1048A>G:p.Lys350Glu,PMS2:NM_001322015.1:missense_variant:MODERATE:exon11/15:c.1312A>G:p.Lys438Glu,PMS2:NR_136154.1:non_coding_transcript_exon_variant:MODIFIER:exon11/15:n.1708A>G:						rs2228006	0.883187	0.85139236727315	0.8176188	COSM4162329	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030365.3 [benign]; RCV000034619.3 [benign]; RCV000212862.1 [benign]; RCV000121840.3 [benign]; 	BM1497492 [CLASS=R MUT=REF PHEN="Colorectal cancer non-polyposis" GENE=PMS2]; 	1.443000	T	T,T,T,T	B,B,B	T,T,D	0.14	0		2412	802	1	[1] Tanja Benkert 16.04.2015	n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	6026988	6026988	G	A	1.0000	77		1649.0	32|45|0,0|0|0,1|1	PMS2	missense_variant,non_coding_transcript_exon_variant	PMS2:NM_001322014.1:missense_variant:MODERATE:exon11/15:c.1408C>T:p.Pro470Ser,PMS2:NM_001322005.1:missense_variant:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_001322009.1:missense_variant:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_000535.6:missense_variant:MODERATE:exon11/15:c.1408C>T:p.Pro470Ser,PMS2:NM_001322003.1:missense_variant:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_001322004.1:missense_variant:MODERATE:exon10/14:c.1003C>T:p.Pro335Ser,PMS2:NM_001322006.1:missense_variant:MODERATE:exon10/14:c.1252C>T:p.Pro418Ser,PMS2:NM_001322007.1:missense_variant:MODERATE:exon10/14:c.1090C>T:p.Pro364Ser,PMS2:NM_001322008.1:missense_variant:MODERATE:exon9/13:c.1090C>T:p.Pro364Ser,PMS2:NM_001322010.1:missense_variant:MODERATE:exon9/13:c.847C>T:p.Pro283Ser,PMS2:NM_001322011.1:missense_variant:MODERATE:exon11/15:c.475C>T:p.Pro159Ser,PMS2:NM_001322012.1:missense_variant:MODERATE:exon11/15:c.475C>T:p.Pro159Ser,PMS2:NM_001322013.1:missense_variant:MODERATE:exon10/14:c.835C>T:p.Pro279Ser,PMS2:NM_001322015.1:missense_variant:MODERATE:exon11/15:c.1099C>T:p.Pro367Ser,PMS2:NR_136154.1:non_coding_transcript_exon_variant:MODIFIER:exon11/15:n.1495C>T:						rs1805321	0.358227	0.3853929807217	0.3781446	COSM3736445	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030364.4 [benign]; RCV000034614.1 [benign]; RCV000079103.7 [benign]; RCV000130721.2 [benign]; RCV000144645.1 [benign]; 		0.265000	T	T,T,T,T	B,B,B	T,T,D	0.09	0		590	1569	1	[1] old entry - no details available	n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	6036980	6036980	G	C	1.0000	165		5197.0	164|1|0,0|0|0,2|1	PMS2	synonymous_variant,5_prime_UTR_variant,non_coding_transcript_exon_variant	PMS2:NM_001322014.1:synonymous_variant:LOW:exon7/15:c.780C>G:p.Ser260Ser,PMS2:NM_001322005.1:synonymous_variant:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_001322009.1:synonymous_variant:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_000535.6:synonymous_variant:LOW:exon7/15:c.780C>G:p.Ser260Ser,PMS2:NM_001322003.1:synonymous_variant:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_001322004.1:synonymous_variant:LOW:exon6/14:c.375C>G:p.Ser125Ser,PMS2:NM_001322006.1:synonymous_variant:LOW:exon7/14:c.780C>G:p.Ser260Ser,PMS2:NM_001322007.1:synonymous_variant:LOW:exon6/14:c.462C>G:p.Ser154Ser,PMS2:NM_001322008.1:synonymous_variant:LOW:exon5/13:c.462C>G:p.Ser154Ser,PMS2:NM_001322010.1:synonymous_variant:LOW:exon6/13:c.375C>G:p.Ser125Ser,PMS2:NM_001322013.1:synonymous_variant:LOW:exon6/14:c.207C>G:p.Ser69Ser,PMS2:NM_001322015.1:synonymous_variant:LOW:exon7/15:c.471C>G:p.Ser157Ser,PMS2:NM_001322011.1:5_prime_UTR_variant:MODIFIER:exon7/15:c.-154C>G:,PMS2:NM_001322012.1:5_prime_UTR_variant:MODIFIER:exon7/15:c.-154C>G:,PMS2:NR_136154.1:non_coding_transcript_exon_variant:MODIFIER:exon7/15:n.867C>G:						rs1805319	0.83127	0.81085741763253	0.7970149	COSM4162330	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000162392.1 [benign]; RCV000030372.4 [benign]; RCV000079112.6 [benign]; RCV000131484.2 [benign]; RCV000229294.1 [likely benign]; 								0		2210	959	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	6037058	6037059	AA	-	0.2813	32		111.0	28|1|0,8|0|0,1|1	PMS2	splice_region_variant&intron_variant	PMS2:NM_001322014.1:splice_region_variant&intron_variant:LOW:exon6/14:c.706-5_706-4delTT:,PMS2:NM_001322005.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-5_301-4delTT:,PMS2:NM_001322009.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-5_301-4delTT:,PMS2:NM_000535.6:splice_region_variant&intron_variant:LOW:exon6/14:c.706-5_706-4delTT:,PMS2:NM_001322003.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-5_301-4delTT:,PMS2:NM_001322004.1:splice_region_variant&intron_variant:LOW:exon5/13:c.301-5_301-4delTT:,PMS2:NM_001322006.1:splice_region_variant&intron_variant:LOW:exon6/13:c.706-5_706-4delTT:,PMS2:NM_001322007.1:splice_region_variant&intron_variant:LOW:exon5/13:c.388-5_388-4delTT:,PMS2:NM_001322008.1:splice_region_variant&intron_variant:LOW:exon4/12:c.388-5_388-4delTT:,PMS2:NM_001322010.1:splice_region_variant&intron_variant:LOW:exon5/12:c.301-5_301-4delTT:,PMS2:NM_001322011.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-228-5_-228-4delTT:,PMS2:NM_001322012.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-228-5_-228-4delTT:,PMS2:NM_001322013.1:splice_region_variant&intron_variant:LOW:exon5/13:c.133-5_133-4delTT:,PMS2:NM_001322015.1:splice_region_variant&intron_variant:LOW:exon6/14:c.397-5_397-4delTT:,PMS2:NR_136154.1:splice_region_variant&intron_variant:LOW:exon6/14:n.793-5_793-4delTT:						rs531184698;rs776641246	0.0916534	0.14631197097944	0.0953867	COSM1735836	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000202811.1 [benign]; 								0		9	282	1	[1] old entry - no details available	n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	6037058	6037058	A	-	0.4688	32		111.0	28|1|0,8|0|0,1|1	PMS2	splice_region_variant&intron_variant	PMS2:NM_001322014.1:splice_region_variant&intron_variant:LOW:exon6/14:c.706-4delT:,PMS2:NM_001322005.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-4delT:,PMS2:NM_001322009.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-4delT:,PMS2:NM_000535.6:splice_region_variant&intron_variant:LOW:exon6/14:c.706-4delT:,PMS2:NM_001322003.1:splice_region_variant&intron_variant:LOW:exon6/14:c.301-4delT:,PMS2:NM_001322004.1:splice_region_variant&intron_variant:LOW:exon5/13:c.301-4delT:,PMS2:NM_001322006.1:splice_region_variant&intron_variant:LOW:exon6/13:c.706-4delT:,PMS2:NM_001322007.1:splice_region_variant&intron_variant:LOW:exon5/13:c.388-4delT:,PMS2:NM_001322008.1:splice_region_variant&intron_variant:LOW:exon4/12:c.388-4delT:,PMS2:NM_001322010.1:splice_region_variant&intron_variant:LOW:exon5/12:c.301-4delT:,PMS2:NM_001322011.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-228-4delT:,PMS2:NM_001322012.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-228-4delT:,PMS2:NM_001322013.1:splice_region_variant&intron_variant:LOW:exon5/13:c.133-4delT:,PMS2:NM_001322015.1:splice_region_variant&intron_variant:LOW:exon6/14:c.397-4delT:,PMS2:NR_136154.1:splice_region_variant&intron_variant:LOW:exon6/14:n.793-4delT:						rs549498051;rs549793612;rs60794673;rs796382014	0.453075	0.44224527461338	0.3329111		600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000203188.1 [benign]; RCV000415703.1,RCV000203188.1 [uncertain significance,benign]; RCV000415703.1 [uncertain significance]; 								0		292	1916			n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	6038722	6038722	T	C	1.0000	36		965.0	34|2|0,0|0|0,1|1	PMS2	splice_region_variant&intron_variant,intron_variant	PMS2:NM_001322014.1:splice_region_variant&intron_variant:LOW:exon6/14:c.705+17A>G:,PMS2:NM_001322005.1:splice_region_variant&intron_variant:LOW:exon6/14:c.300+17A>G:,PMS2:NM_001322009.1:splice_region_variant&intron_variant:LOW:exon6/14:c.300+17A>G:,PMS2:NM_000535.6:splice_region_variant&intron_variant:LOW:exon6/14:c.705+17A>G:,PMS2:NM_001322003.1:splice_region_variant&intron_variant:LOW:exon6/14:c.300+17A>G:,PMS2:NM_001322004.1:splice_region_variant&intron_variant:LOW:exon5/13:c.300+17A>G:,PMS2:NM_001322006.1:splice_region_variant&intron_variant:LOW:exon6/13:c.705+17A>G:,PMS2:NM_001322007.1:splice_region_variant&intron_variant:LOW:exon5/13:c.387+17A>G:,PMS2:NM_001322008.1:splice_region_variant&intron_variant:LOW:exon4/12:c.387+17A>G:,PMS2:NM_001322010.1:splice_region_variant&intron_variant:LOW:exon5/12:c.300+17A>G:,PMS2:NM_001322011.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-229+17A>G:,PMS2:NM_001322012.1:splice_region_variant&intron_variant:LOW:exon6/14:c.-229+17A>G:,PMS2:NM_001322015.1:splice_region_variant&intron_variant:LOW:exon6/14:c.396+17A>G:,PMS2:NR_136154.1:splice_region_variant&intron_variant:LOW:exon6/14:n.792+17A>G:,PMS2:NM_001322013.1:intron_variant:MODIFIER:exon5/13:c.133-1668A>G:						rs62456182	0.325679	0.36775756377299	0.3613219		600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030371.3 [benign]; RCV000079110.5 [benign]; RCV000130741.1 [benign]; 								0		235	650			n/a	n/a	PMS2 (inh=AR+AD pLI=0.00)
chr7	55214348	55214348	C	T	1.0000	173		5555.0	77|96|0,0|0|0,2|2	EGFR	synonymous_variant	EGFR:NM_005228.3:synonymous_variant:LOW:exon4/28:c.474C>T:p.Asn158Asn,EGFR:NM_201283.1:synonymous_variant:LOW:exon4/10:c.474C>T:p.Asn158Asn,EGFR:NM_201282.1:synonymous_variant:LOW:exon4/16:c.474C>T:p.Asn158Asn,EGFR:NM_201284.1:synonymous_variant:LOW:exon4/16:c.474C>T:p.Asn158Asn						rs2072454	0.475439	0.50898583700186	0.5027202	COSM1451542, COSM42978	131550 [EGFR (confirmed) Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980|Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980|Nonsmall cell lung cancer,susceptibility to,211980|Inflammatory skin and bowel disease,neonatal,2,616069];	RCV000253696.1 [benign]; RCV000324154.1 [likely benign]; 		1.216000					15.58	2	TEST_SomaticAndTreatment,	360	692			n/a	n/a	EGFR (inh=AR pLI=1.00)
chr7	116397572	116397572	A	G	0.5361	97		1144.0	45|7|0,38|7|0,2|1	MET	synonymous_variant	MET:NM_001127500.2:synonymous_variant:LOW:exon7/21:c.1944A>G:p.Gln648Gln,MET:NM_001324402.1:synonymous_variant:LOW:exon6/20:c.654A>G:p.Gln218Gln,MET:NM_001324401.1:synonymous_variant:LOW:exon7/12:c.1944A>G:p.Gln648Gln,MET:NM_000245.3:synonymous_variant:LOW:exon7/21:c.1944A>G:p.Gln648Gln		Cytokine-cytokine receptor interaction;Axon guidance;Focal adhesion;Adherens junction;Epithelial cell signaling in Helicobacter pylori infection;Colorectal cancer;Renal cell carcinoma;Melanoma	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells	CBL mediated ligand-induced downregulation of EGF receptors;Signaling of Hepatocyte Growth Factor Receptor		rs13223756	0.187899	0.18781422669122	0.1872556		164860 [MET (confirmed) Renal cell carcinoma,papillary,1,familial and somatic,605074|Hepatocellular carcinoma,childhood type,somatic,114550|Deafness,autosomal recessive 97,616705|Osteofibrous dysplasia,susceptibility to,607278];	RCV000079486.5 [benign]; RCV000162945.1 [benign]; RCV000307503.1 [benign]; 								2	SomaticAndTreatment,	58	452			n/a	n/a	MET (inh=AD pLI=1.00)
chr7	116435768	116435768	C	T	0.5600	250		3513.0	98|42|0,86|24|0,1|1	MET	synonymous_variant	MET:NM_001127500.2:synonymous_variant:LOW:exon20/21:c.3912C>T:p.Asp1304Asp,MET:NM_001324402.1:synonymous_variant:LOW:exon19/20:c.2568C>T:p.Asp856Asp,MET:NM_000245.3:synonymous_variant:LOW:exon20/21:c.3858C>T:p.Asp1286Asp		Cytokine-cytokine receptor interaction;Axon guidance;Focal adhesion;Adherens junction;Epithelial cell signaling in Helicobacter pylori infection;Colorectal cancer;Renal cell carcinoma;Melanoma	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells	CBL mediated ligand-induced downregulation of EGF receptors;Signaling of Hepatocyte Growth Factor Receptor		rs41736	0.352236	0.42283991518685	0.4034044	COSM150377	164860 [MET (confirmed) Renal cell carcinoma,papillary,1,familial and somatic,605074|Hepatocellular carcinoma,childhood type,somatic,114550|Deafness,autosomal recessive 97,616705|Osteofibrous dysplasia,susceptibility to,607278];	RCV000079492.5 [benign]; RCV000162950.1 [benign]; RCV000351242.1 [benign]; 								4	GT,TEST_SomaticAndTreatment,	266	732			n/a	n/a	MET (inh=AD pLI=1.00)
chr7	116436022	116436022	G	A	0.5741	108		1568.0	40|22|0,26|20|0,1|1	MET	synonymous_variant	MET:NM_001127500.2:synonymous_variant:LOW:exon21/21:c.4071G>A:p.Ala1357Ala,MET:NM_001324402.1:synonymous_variant:LOW:exon20/20:c.2727G>A:p.Ala909Ala,MET:NM_000245.3:synonymous_variant:LOW:exon21/21:c.4017G>A:p.Ala1339Ala		Cytokine-cytokine receptor interaction;Axon guidance;Focal adhesion;Adherens junction;Epithelial cell signaling in Helicobacter pylori infection;Colorectal cancer;Renal cell carcinoma;Melanoma	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells	CBL mediated ligand-induced downregulation of EGF receptors;Signaling of Hepatocyte Growth Factor Receptor		rs2023748	0.353834	0.42452580137497	0.4210052	COSM150378	164860 [MET (confirmed) Renal cell carcinoma,papillary,1,familial and somatic,605074|Hepatocellular carcinoma,childhood type,somatic,114550|Deafness,autosomal recessive 97,616705|Osteofibrous dysplasia,susceptibility to,607278];	RCV000079493.5 [benign]; RCV000162951.1 [benign]; RCV000389579.1 [benign]; RCV000204951.1 [likely benign]; 								4	GT,TEST_SomaticAndTreatment,	271	728			n/a	n/a	MET (inh=AD pLI=1.00)
chr7	116436097	116436097	G	A	0.5439	171		2542.0	68|25|0,48|30|0,1|2	MET	synonymous_variant	MET:NM_001127500.2:synonymous_variant:LOW:exon21/21:c.4146G>A:p.Pro1382Pro,MET:NM_001324402.1:synonymous_variant:LOW:exon20/20:c.2802G>A:p.Pro934Pro,MET:NM_000245.3:synonymous_variant:LOW:exon21/21:c.4092G>A:p.Pro1364Pro		Cytokine-cytokine receptor interaction;Axon guidance;Focal adhesion;Adherens junction;Epithelial cell signaling in Helicobacter pylori infection;Colorectal cancer;Renal cell carcinoma;Melanoma	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells	CBL mediated ligand-induced downregulation of EGF receptors;Signaling of Hepatocyte Growth Factor Receptor		rs41737	0.354633	0.42478257268285	0.4095715	COSM150379	164860 [MET (confirmed) Renal cell carcinoma,papillary,1,familial and somatic,605074|Hepatocellular carcinoma,childhood type,somatic,114550|Deafness,autosomal recessive 97,616705|Osteofibrous dysplasia,susceptibility to,607278];	RCV000079494.5 [benign]; RCV000162952.1 [benign]; RCV000310007.1 [benign]; 								4	GT,TEST_SomaticAndTreatment,	270	729			n/a	n/a	MET (inh=AD pLI=1.00)
chr10	123239112	123239112	G	A	0.4563	103		903.0	0|47|0,0|56|0,1|2	FGFR2	synonymous_variant,3_prime_UTR_variant,non_coding_transcript_exon_variant	FGFR2:NM_001144915.1:synonymous_variant:LOW:exon17/17:c.2107C>T:p.Leu703Leu,FGFR2:NM_022970.3:3_prime_UTR_variant:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NM_001320654.1:3_prime_UTR_variant:MODIFIER:exon17/17:c.*259C>T:,FGFR2:NM_001144914.1:3_prime_UTR_variant:MODIFIER:exon15/15:c.*259C>T:,FGFR2:NM_023029.2:3_prime_UTR_variant:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001144916.1:3_prime_UTR_variant:MODIFIER:exon15/15:c.*259C>T:,FGFR2:NM_000141.4:3_prime_UTR_variant:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NM_001144917.1:3_prime_UTR_variant:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001144918.1:3_prime_UTR_variant:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001320658.1:3_prime_UTR_variant:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NR_073009.1:non_coding_transcript_exon_variant:MODIFIER:exon17/17:n.3175C>T:						rs1047057	0.414337	0.5310510334019	0.1984515	COSM147070	176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000264030.1 [benign]; RCV000302746.1 [benign]; RCV000304323.1 [benign]; RCV000310102.1 [benign]; RCV000343896.1 [benign]; RCV000355233.1 [benign]; RCV000361106.1 [benign]; RCV000398132.1 [benign]; RCV000398152.1 [benign]; 								2	TEST_SomaticAndTreatment,	470	714			n/a	n/a	FGFR2 (inh=AR+AD pLI=1.00)
chr10	123298158	123298158	T	C	1.0000	235		7763.0	108|127|0,0|0|0,2|3	FGFR2	synonymous_variant,non_coding_transcript_exon_variant	FGFR2:NM_022970.3:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144914.1:synonymous_variant:LOW:exon5/15:c.696A>G:p.Val232Val,FGFR2:NM_023029.2:synonymous_variant:LOW:exon4/16:c.429A>G:p.Val143Val,FGFR2:NM_001144916.1:synonymous_variant:LOW:exon3/15:c.351A>G:p.Val117Val,FGFR2:NM_001144915.1:synonymous_variant:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NM_000141.4:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144917.1:synonymous_variant:LOW:exon6/16:c.696A>G:p.Val232Val,FGFR2:NM_001144918.1:synonymous_variant:LOW:exon4/16:c.351A>G:p.Val117Val,FGFR2:NM_001320658.1:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144913.1:synonymous_variant:LOW:exon5/17:c.696A>G:p.Val232Val,FGFR2:NM_001144919.1:synonymous_variant:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NR_073009.1:non_coding_transcript_exon_variant:MODIFIER:exon4/17:n.998A>G:						rs1047100	0.795327	0.77968000790918	0.7744817		176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000250550.1 [benign]; RCV000264031.1 [benign]; RCV000268420.1 [benign]; RCV000270961.1 [benign]; RCV000308616.1 [benign]; RCV000316516.1 [benign]; RCV000321550.1 [benign]; RCV000363146.1 [benign]; RCV000365600.1 [benign]; RCV000378516.1 [benign]; 								0		930	479			n/a	n/a	FGFR2 (inh=AR+AD pLI=1.00)
chr12	25368462	25368462	C	T	1.0000	398		12804.0	284|114|0,0|0|0,2|1	KRAS	synonymous_variant,intron_variant	KRAS:NM_033360.3:synonymous_variant:LOW:exon5/6:c.483G>A:p.Arg161Arg,KRAS:NM_004985.4:intron_variant:MODIFIER:exon4/4:c.451-5617G>A:		MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity	Telomeres, Telomerase, Cellular Aging, and  Immortality		rs4362222	0.997604	0.99953862378065	0.9349341		190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000150886.1 [benign]; RCV000039808.3 [benign]; RCV000149847.3 [benign]; 								0		1547	0			n/a	n/a	KRAS (inh=AD pLI=0.00)
chr12	133202215	133202215	G	A	0.4348	46		316.0	17|3|0,20|6|0,1|1	POLE	splice_region_variant&intron_variant	POLE:NM_006231.3:splice_region_variant&intron_variant:LOW:exon47/48:c.6657+16C>T:		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5745075	0.423323	0.37031547569761	0.3626595		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];	RCV000410858.1 [benign]; 								0		96	462			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133208886	133208886	C	T	0.5319	47		461.0	15|10|0,16|6|0,1|1	POLE	splice_region_variant&intron_variant	POLE:NM_006231.3:splice_region_variant&intron_variant:LOW:exon45/48:c.6330+15G>A:		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5745023	0.565096	0.49405201962497	0.4816854		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									0		198	515			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133208979	133208979	T	C	0.5319	47		458.0	15|10|0,16|6|0,1|1	POLE	synonymous_variant	POLE:NM_006231.3:synonymous_variant:LOW:exon45/49:c.6252A>G:p.Ser2084Ser		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5745022	0.699081	0.63814303845456	0.6317780		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									0		481	657			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133219831	133219831	T	C	0.5000	82		981.0	15|26|0,20|20|0,1|2	POLE	synonymous_variant	POLE:NM_006231.3:synonymous_variant:LOW:exon35/49:c.4530A>G:p.Ala1510Ala		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5744944	0.605232	0.5032032032032	0.4952927	COSM4146902, COSM4146901	174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									0		264	667			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133233705	133233705	T	C	1.0000	81		1978.0	29|52|0,0|0|0,1|1	POLE	splice_region_variant&intron_variant	POLE:NM_006231.3:splice_region_variant&intron_variant:LOW:exon29/48:c.3582+17A>G:		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5744889	0.983826	0.97117238878542	0.9414355		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									0		1016	66			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133236000	133236000	C	T	0.3333	54		332.0	14|4|0,30|6|0,1|1	POLE	synonymous_variant	POLE:NM_006231.3:synonymous_variant:LOW:exon26/49:c.3156G>A:p.Thr1052Thr		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs5744857	0.605431	0.50285167968879	0.4972605		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									0		264	668			n/a	n/a	POLE (inh=AR pLI=0.00)
chr12	133252796	133252796	C	G	0.5000	46		560.0	14|9|0,22|1|0,1|1	POLE	splice_region_variant&intron_variant	POLE:NM_006231.3:splice_region_variant&intron_variant:LOW:exon9/48:c.910-6G>C:		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication			rs4077170	0.571685	0.63067222718697	0.6178105		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];									1	Leuk,	635	591			n/a	n/a	POLE (inh=AR pLI=0.00)
chr13	32912299	32912299	T	C	0.3750	16		90.0	2|4|0,0|10|0,1|1	BRCA2	synonymous_variant	BRCA2:NM_000059.3:synonymous_variant:LOW:exon11/27:c.3807T>C:p.Val1269Val		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs543304	0.168131	0.18984467254065	0.1742656		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113220.4 [benign]; RCV000123965.2 [benign]; RCV000130362.2 [benign]; RCV000152874.5 [benign]; RCV000316398.1 [benign]; RCV000354795.1 [benign]; RCV000113221.1 [benign]; 								1	Leuk,	119	1077	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr13	32913055	32913055	A	G	1.0000	253		7931.0	218|35|0,0|0|0,1|2	BRCA2	synonymous_variant	BRCA2:NM_000059.3:synonymous_variant:LOW:exon11/27:c.4563A>G:p.Leu1521Leu		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs206075	0.974042	0.99313788713064	0.9550815		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113321.1 [benign]; RCV000160224.1 [benign]; RCV000164515.2 [likely benign]; RCV000198429.1 [likely benign]; RCV000412372.1 [likely benign]; RCV000119245.2 [benign]; RCV000132170.2 [benign]; RCV000152875.8 [benign]; RCV000257902.2 [benign]; RCV000340564.1 [benign]; 								0		3373	11	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr13	32915005	32915005	G	C	1.0000	29		929.0	22|7|0,0|0|0,1|2	BRCA2	synonymous_variant	BRCA2:NM_000059.3:synonymous_variant:LOW:exon11/27:c.6513G>C:p.Val2171Val		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs206076	0.973642	0.99303225166548	0.9628177	COSM4147690, COSM4147689	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113602.1 [not provided]; RCV000119246.2 [benign]; RCV000152878.8 [benign]; RCV000162377.1 [benign]; RCV000257903.2 [benign]; RCV000261979.1 [benign]; RCV000163332.1 [likely benign]; RCV000168590.4 [other]; RCV000195987.2 [other]; 								0		3374	14	1	[1] old entry - no details available	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr13	32936646	32936646	T	C	0.5833	24		301.0	8|6|0,8|2|0,1|1	BRCA2	splice_region_variant&intron_variant	BRCA2:NM_000059.3:splice_region_variant&intron_variant:LOW:exon16/26:c.7806-14T>C:		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs9534262	0.53155	0.52082850041425	0.5131701		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113823.3 [benign]; RCV000124004.2 [benign]; RCV000132168.2 [benign]; RCV000152883.5 [benign]; RCV000331967.1 [benign]; RCV000386451.1 [benign]; 	CS147979 [CLASS=FP MUT=ALT PHEN="Alternative splicing" GENE=BRCA2]; 							3	SomaticAndTreatment,	376	744	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr16	68842480	68842480	G	C	0.6552	58		953.0	20|18|0,8|12|0,1|1	CDH1	splice_region_variant&intron_variant	CDH1:NM_004360.4:splice_region_variant&intron_variant:LOW:exon4/15:c.531+10G>C:,CDH1:NM_001317184.1:splice_region_variant&intron_variant:LOW:exon4/14:c.531+10G>C:,CDH1:NM_001317185.1:splice_region_variant&intron_variant:LOW:exon4/15:c.-1085+10G>C:,CDH1:NM_001317186.1:splice_region_variant&intron_variant:LOW:exon4/14:c.-1289+10G>C:						rs33963999	0.0179712	0.038281585821512	0.0385585		192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089|Ovarian carcinoma,somatic,167000|Breast cancer,lobular,114480|Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215|Prostate cancer,susceptibility to,176807];	RCV000119115.3 [other]; RCV000132274.1 [benign]; RCV000242153.1 [benign]; 								0		10	278	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	CDH1 (inh=AD pLI=0.34)
chr16	68857441	68857441	T	C	0.5205	146		1924.0	30|46|0,26|44|0,1|1	CDH1	synonymous_variant	CDH1:NM_004360.4:synonymous_variant:LOW:exon13/16:c.2076T>C:p.Ala692Ala,CDH1:NM_001317184.1:synonymous_variant:LOW:exon12/15:c.1893T>C:p.Ala631Ala,CDH1:NM_001317185.1:synonymous_variant:LOW:exon13/16:c.528T>C:p.Ala176Ala,CDH1:NM_001317186.1:synonymous_variant:LOW:exon12/15:c.111T>C:p.Ala37Ala						rs1801552	0.71865	0.65480761308396	0.6414433	COSM3755010	192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089|Ovarian carcinoma,somatic,167000|Breast cancer,lobular,114480|Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215|Prostate cancer,susceptibility to,176807];	RCV000132164.2 [benign]; RCV000246442.1 [benign]; RCV000293455.1 [benign]; 	CM1414917 [CLASS=DP MUT=ALT PHEN="Gastric cancer early-onset diffuse association with" GENE=CDH1]; 							4	SomaticAndTreatment,TEST_SomaticAndTreatment,	1264	1515	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	CDH1 (inh=AD pLI=0.34)
chr17	7579472	7579472	G	C	1.0000	15		458.0	10|5|0,0|0|0,1|1	TP53	missense_variant	TP53:NM_000546.5:missense_variant:MODERATE:exon4/11:c.215C>G:p.Pro72Arg,TP53:NM_001126112.2:missense_variant:MODERATE:exon4/11:c.215C>G:p.Pro72Arg,TP53:NM_001126113.2:missense_variant:MODERATE:exon4/12:c.215C>G:p.Pro72Arg,TP53:NM_001126114.2:missense_variant:MODERATE:exon4/12:c.215C>G:p.Pro72Arg,TP53:NM_001126118.1:missense_variant:MODERATE:exon3/10:c.98C>G:p.Pro33Arg,TP53:NM_001276695.1:missense_variant:MODERATE:exon4/12:c.98C>G:p.Pro33Arg,TP53:NM_001276696.1:missense_variant:MODERATE:exon4/12:c.98C>G:p.Pro33Arg,TP53:NM_001276760.1:missense_variant:MODERATE:exon4/11:c.98C>G:p.Pro33Arg,TP53:NM_001276761.1:missense_variant:MODERATE:exon4/11:c.98C>G:p.Pro33Arg						rs1042522	0.542931	0.65995997486024	0.6429160	COSM250061, COSM3766192, COSM3766191, COSM3766190, COSM3766193	191170 [TP53 (confirmed) Colorectal cancer,114500|Li-Fraumeni syndrome,151623|Hepatocellular carcinoma,114550|Osteosarcoma,259500|Choroid plexus papilloma,260500|Nasopharyngeal carcinoma,607107|Pancreatic cancer,260350|Adrenal cortical carcinoma,202300|Breast cancer,114480|Basal cell carcinoma 7,614740|Glioma susceptibility 1,137800];	RCV000152112.1 [benign]; RCV000013144.4 [benign]; RCV000034639.1 [benign]; RCV000079202.7 [benign]; RCV000132165.3 [benign]; RCV000144668.1 [uncertain significance]; RCV000211157.1 [drug response]; RCV000211212.1 [drug response]; RCV000211311.1 [drug response]; RCV000211338.1 [drug response]; RCV000211395.1 [drug response]; RCV000300782.1 [benign]; RCV000164487.1 [uncertain significance]; RCV000227427.1 [uncertain significance]; 	CM961374 [CLASS=DFP MUT=REF PHEN="Lung cancer association with" GENE=TP53]; 	1.015000	T	T,T,T,T,T,T,T,T,T	B,B,B,B,B	D,D,D,D,D,D,D,D	0.36	1	TEST_SomaticAndTreatment,	1740	1288	1	[1] old entry - no details available	n/a	n/a	TP53 (inh=AD pLI=0.91)
chr17	37868715	37868715	C	T	1.0000	112		3576.0	78|34|0,0|0|0,1|1	ERBB2	splice_region_variant&intron_variant	ERBB2:NM_004448.3:splice_region_variant&intron_variant:LOW:exon9/26:c.1148+14C>T:,ERBB2:NM_001289938.1:splice_region_variant&intron_variant:LOW:exon12/17:c.1058+14C>T:,ERBB2:NM_001005862.2:splice_region_variant&intron_variant:LOW:exon12/29:c.1058+14C>T:,ERBB2:NM_001289936.1:splice_region_variant&intron_variant:LOW:exon13/30:c.1103+14C>T:,ERBB2:NM_001289937.1:splice_region_variant&intron_variant:LOW:exon9/25:c.1148+14C>T:,ERBB2:NR_110535.1:splice_region_variant&intron_variant:LOW:exon9/26:n.1472+14C>T:		ErbB signaling pathway;Calcium signaling pathway;Focal adhesion;Adherens junction;Pancreatic cancer;Endometrial cancer;Prostate cancer;Bladder cancer;Non-small cell lung cancer	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization			rs4252627	0.444489	0.60581819432976	0.5824287	COSN165414	164870 [ERBB2 (confirmed) Adenocarcinoma of lung,somatic,211980|Glioblastoma,somatic,137800|Gastric cancer,somatic,613659|Ovarian cancer,somatic,];									2	TEST_SomaticAndTreatment,	266	274			n/a	n/a	ERBB2 (inh=AR+AD pLI=1.00)
chr17	37884037	37884037	C	G	1.0000	17		452.0	1|16|0,0|0|0,2|2	ERBB2	missense_variant,3_prime_UTR_variant,non_coding_transcript_exon_variant	ERBB2:NM_004448.3:missense_variant:MODERATE:exon27/27:c.3508C>G:p.Pro1170Ala,ERBB2:NM_001005862.2:missense_variant:MODERATE:exon30/30:c.3418C>G:p.Pro1140Ala,ERBB2:NM_001289936.1:missense_variant:MODERATE:exon31/31:c.3463C>G:p.Pro1155Ala,ERBB2:NM_001289937.1:3_prime_UTR_variant:MODIFIER:exon26/26:c.*87C>G:,ERBB2:NR_110535.1:non_coding_transcript_exon_variant:MODIFIER:exon27/27:n.3832C>G:		ErbB signaling pathway;Calcium signaling pathway;Focal adhesion;Adherens junction;Pancreatic cancer;Endometrial cancer;Prostate cancer;Bladder cancer;Non-small cell lung cancer	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization			rs1058808	0.452077	0.60698188833635	0.5957467		164870 [ERBB2 (confirmed) Adenocarcinoma of lung,somatic,211980|Glioblastoma,somatic,137800|Gastric cancer,somatic,613659|Ovarian cancer,somatic,];	RCV000120753.1 [not provided]; 	CM087578 [CLASS=DP MUT=ALT PHEN="Lung cancer increased risk in females non-smokers and non-drinkers" GENE=ERBB2]; 	3.926000	T	D,D,D,D,D	P,B,P	T,T,T,T,T	23.70	3	TEST_SomaticAndTreatment,	610	577			n/a	n/a	ERBB2 (inh=AR+AD pLI=1.00)
chr17	41223094	41223094	T	C	1.0000	113		3486.0	8|105|0,0|0|0,1|1	BRCA1	missense_variant,sequence_feature,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:missense_variant:MODERATE:exon16/24:c.4900A>G:p.Ser1634Gly,BRCA1:NM_007298.3:missense_variant:MODERATE:exon14/22:c.1525A>G:p.Ser509Gly,BRCA1:NM_007297.3:missense_variant:MODERATE:exon14/22:c.4696A>G:p.Ser1566Gly,BRCA1:NM_007299.3:missense_variant:MODERATE:exon15/22:c.1525A>G:p.Ser509Gly,BRCA1:NM_007294.3:missense_variant:MODERATE:exon15/23:c.4837A>G:p.Ser1613Gly,BRCA1:NM_007300.3:sequence_feature:MODERATE:exon16/24:c.4900A>G:,BRCA1:NM_007298.3:sequence_feature:MODERATE:exon14/22:c.1525A>G:,BRCA1:NM_007297.3:sequence_feature:MODERATE:exon14/22:c.4696A>G:,BRCA1:NM_007299.3:sequence_feature:MODERATE:exon15/22:c.1525A>G:,BRCA1:NM_007294.3:sequence_feature:MODERATE:exon15/23:c.4837A>G:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon15/23:n.4973A>G:	BRCT__1_	Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs1799966	0.355831	0.34957152274225	0.3439140	COSM3755560, COSM3755559	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000031194.5 [other]; RCV000048673.4 [likely benign]; RCV000130704.3 [likely benign]; RCV000167795.2 [likely benign]; RCV000034753.3 [benign]; RCV000048672.5 [benign]; RCV000112410.5 [benign]; RCV000119096.3 [other]; RCV000120260.6 [benign]; RCV000128996.3 [benign]; 	CM1210129 [CLASS=R MUT=ALT PHEN="Breast cancer" GENE=BRCA1]; 	-0.112000	T	D,T,D,T,D,T,T,T,D,,D,D,D	B,B,B,B,B,B,B,B	D,D,D,D,D,D,D,D,D,D	0.55	5	ERC_Mutaediting_NOQBIC,GT,TEST_SomaticAndTreatment,	393	1426	2	[2] old entry - no details available	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41234470	41234470	A	G	0.9926	271		8774.0	64|205|0,2|0|0,1|2	BRCA1	synonymous_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:synonymous_variant:LOW:exon12/24:c.4308T>C:p.Ser1436Ser,BRCA1:NM_007298.3:synonymous_variant:LOW:exon11/22:c.999T>C:p.Ser333Ser,BRCA1:NM_007297.3:synonymous_variant:LOW:exon11/22:c.4167T>C:p.Ser1389Ser,BRCA1:NM_007299.3:synonymous_variant:LOW:exon12/22:c.999T>C:p.Ser333Ser,BRCA1:NM_007294.3:synonymous_variant:LOW:exon12/23:c.4308T>C:p.Ser1436Ser,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon12/23:n.4444T>C:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs1060915	0.336262	0.34310171530261	0.3379527		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000112313.5 [benign]; RCV000114988.2 [benign]; RCV000128938.2 [benign]; RCV000152866.6 [benign]; RCV000311915.1 [likely benign]; 		-0.119000	T				4.96	5	ERC_Mutaediting_NOQBIC,GT,TEST_SomaticAndTreatment,	389	1422	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41244000	41244000	T	C	0.9951	205		6190.0	48|156|0,0|0|0,2|2	BRCA1	missense_variant,intron_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:missense_variant:MODERATE:exon10/24:c.3548A>G:p.Lys1183Arg,BRCA1:NM_007297.3:missense_variant:MODERATE:exon9/22:c.3407A>G:p.Lys1136Arg,BRCA1:NM_007294.3:missense_variant:MODERATE:exon10/23:c.3548A>G:p.Lys1183Arg,BRCA1:NM_007298.3:intron_variant:MODIFIER:exon9/21:c.788-951A>G:,BRCA1:NM_007299.3:intron_variant:MODIFIER:exon10/21:c.788-951A>G:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon10/23:n.3684A>G:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs16942	0.352636	0.34900473619713	0.3419333	COSM3755561, COSM148277	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000034742.3 [benign]; RCV000048229.5 [other]; RCV000112115.5 [benign]; RCV000120278.6 [benign]; RCV000128991.4 [benign]; RCV000157734.1 [benign]; 	CM058359 [CLASS=DP MUT=ALT PHEN="Breast cancer protection against association with" GENE=BRCA1]; 	-0.365000	T	T,T,T,T,T,T,T	B,B,B,B,B,B	T,T,T,T,T,T	0.00	5	ERC_Mutaediting_NOQBIC,GT,TEST_SomaticAndTreatment,	388	1425	1	[1] old entry - no details available	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41244435	41244435	T	C	1.0000	155		4931.0	21|134|0,0|0|0,1|1	BRCA1	missense_variant,intron_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:missense_variant:MODERATE:exon10/24:c.3113A>G:p.Glu1038Gly,BRCA1:NM_007297.3:missense_variant:MODERATE:exon9/22:c.2972A>G:p.Glu991Gly,BRCA1:NM_007294.3:missense_variant:MODERATE:exon10/23:c.3113A>G:p.Glu1038Gly,BRCA1:NM_007298.3:intron_variant:MODIFIER:exon9/21:c.788-1386A>G:,BRCA1:NM_007299.3:intron_variant:MODIFIER:exon10/21:c.788-1386A>G:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon10/23:n.3249A>G:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs16941	0.335663	0.34286561948872	0.3258630	COSM3755563, COSM3755562	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000034738.3 [benign]; RCV000112006.5 [benign]; RCV000114987.2 [benign]; RCV000120276.7 [benign]; RCV000128978.3 [benign]; RCV000353897.1 [likely benign]; RCV000233884.1 [uncertain significance]; 	CM032861 [CLASS=DP MUT=ALT PHEN="Endometriosis association with" GENE=BRCA1]; 	-0.480000	T	D,D,D,D,D,D,D	B,B,B,B,P,B	T,T,T,T,T,T	22.20	4	ERC_Mutaediting_NOQBIC,GT,TEST_SomaticAndTreatment,	386	1424	1	[1] old entry - no details available	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41244936	41244936	G	A	1.0000	226		6927.0	8|218|0,0|0|0,1|1	BRCA1	missense_variant,intron_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:missense_variant:MODERATE:exon10/24:c.2612C>T:p.Pro871Leu,BRCA1:NM_007297.3:missense_variant:MODERATE:exon9/22:c.2471C>T:p.Pro824Leu,BRCA1:NM_007294.3:missense_variant:MODERATE:exon10/23:c.2612C>T:p.Pro871Leu,BRCA1:NM_007298.3:intron_variant:MODIFIER:exon9/21:c.787+1825C>T:,BRCA1:NM_007299.3:intron_variant:MODIFIER:exon10/21:c.787+1825C>T:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon10/23:n.2748C>T:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs799917	0.54393	0.41004977092192	0.4022469	COSM148278, COSM3755564	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000034735.3 [benign]; RCV000111903.5 [benign]; RCV000114986.2 [benign]; RCV000120285.6 [benign]; RCV000132149.4 [benign]; RCV000261383.1 [likely benign]; RCV000077111.2 [likely benign]; RCV000221093.1 [uncertain significance]; RCV000047899.2 [not provided]; RCV000111902.1 [uncertain significance]; 	CM096315 [CLASS=DFP MUT=ALT PHEN="Cervical cancer decreased risk association with" GENE=BRCA1]; 	4.246000	T	T,T,T,T,T,T,T	B,B,B,B,B,B	T,T,T,T,T,T	14.03	2	TEST_SomaticAndTreatment,	432	1443	1	[1] Christopher Schroeder 27.04.2015	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41245237	41245237	A	G	1.0000	100		3196.0	34|66|0,0|0|0,1|2	BRCA1	synonymous_variant,intron_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:synonymous_variant:LOW:exon10/24:c.2311T>C:p.Leu771Leu,BRCA1:NM_007297.3:synonymous_variant:LOW:exon9/22:c.2170T>C:p.Leu724Leu,BRCA1:NM_007294.3:synonymous_variant:LOW:exon10/23:c.2311T>C:p.Leu771Leu,BRCA1:NM_007298.3:intron_variant:MODIFIER:exon9/21:c.787+1524T>C:,BRCA1:NM_007299.3:intron_variant:MODIFIER:exon10/21:c.787+1524T>C:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon10/23:n.2447T>C:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs16940	0.335264	0.34196340257171	0.3275800	COSM3755566, COSM3755565	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000111822.5 [benign]; RCV000114985.2 [benign]; RCV000128982.2 [benign]; RCV000152867.5 [benign]; RCV000264575.1 [likely benign]; 								4	GT,TEST_SomaticAndTreatment,	382	1423	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chr17	41245466	41245466	G	A	1.0000	63		2060.0	44|19|0,0|0|0,1|1	BRCA1	sequence_feature,synonymous_variant,intron_variant,non_coding_transcript_exon_variant	BRCA1:NM_007300.3:sequence_feature:MODERATE:exon10/24:c.2082C>T:,BRCA1:NM_007300.3:sequence_feature:MODERATE:exon10/24:c.2082C>T:,BRCA1:NM_007297.3:sequence_feature:MODERATE:exon9/22:c.1941C>T:,BRCA1:NM_007297.3:sequence_feature:MODERATE:exon9/22:c.1941C>T:,BRCA1:NM_007294.3:sequence_feature:MODERATE:exon10/23:c.2082C>T:,BRCA1:NM_007294.3:sequence_feature:MODERATE:exon10/23:c.2082C>T:,BRCA1:NM_007300.3:synonymous_variant:LOW:exon10/24:c.2082C>T:p.Ser694Ser,BRCA1:NM_007297.3:synonymous_variant:LOW:exon9/22:c.1941C>T:p.Ser647Ser,BRCA1:NM_007294.3:synonymous_variant:LOW:exon10/23:c.2082C>T:p.Ser694Ser,BRCA1:NM_007298.3:intron_variant:MODIFIER:exon9/21:c.787+1295C>T:,BRCA1:NM_007299.3:intron_variant:MODIFIER:exon10/21:c.787+1295C>T:,BRCA1:NR_027676.1:non_coding_transcript_exon_variant:MODIFIER:exon10/23:n.2218C>T:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs1799949	0.336462	0.34826494260457	0.3388080	COSM148280, COSM3755567	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];	RCV000111763.4 [benign]; RCV000114984.2 [benign]; RCV000128966.3 [benign]; RCV000152868.6 [benign]; RCV000322007.1 [likely benign]; 								3	GT,TEST_SomaticAndTreatment,	387	1424	1	[1] Ulrike Faust 13.06.2015	n/a	n/a	BRCA1 (inh=AD pLI=0.00)
chrX	39933339	39933339	A	G	1.0000	116		3483.0	70|46|0,0|0|0,1|1	BCOR	synonymous_variant	BCOR:NM_001123385.1:synonymous_variant:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_017745.5:synonymous_variant:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_001123383.1:synonymous_variant:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_001123384.1:synonymous_variant:LOW:exon4/14:c.1260T>C:p.Asp420Asp						rs5917933	0.903046	0.89524618581318	0.8250977	COSM4156839, COSM4156840	300485 [BCOR (confirmed) Microphthalmia,syndromic 2,300166];	RCV000081809.8 [other]; 								1	Ringversuch_EMQN,	1351	140			n/a	n/a	BCOR (inh=XLD pLI=1.00)
